Институт физико-органической химии

https://ifoch.by/  
220072 Минск, ул. Сурганова 13

Synthetic RNA oligonucleotides, guide RNA for CRISPR genome editing technology, modified RNA oligonucleotides

COUNTRY OF ORIGIN

Belarus

IDENTIFIER

BO12039

PUBLISHED

2024-11-06

LAST UPDATE

2024-11-10

DEADLINE

Linked profile in other language
Responsible
Kristina Kosikova
+375 17 379 1632
info@ifoch.bas-net.by
Summary
Institute of Physical Organic Chemistry offers consumers synthetic RNA oligonucleotides, guide RNA for CRISPR genome editing technology, modified RNA oligonucleotides under a manufacturing agreement and is seeking partners interested in a distribution services agreement.
Description
Developed to solve a national economic problem - ensuring the availability of reagents for molecular biological and genetic research on the domestic market.

The quality is not inferior to world analogues at a lower cost. The possibility of introducing modifications on individual requests in accordance with the customer's tasks.

Scope - For the development of gene therapy drugs, scientific research in the field of molecular biology and genetics.

The technologies are import-substituting and have no analogues on the domestic market. The emergence of affordable domestic RNA oligonucleotides will contribute to the development of domestic biomedicine. On the foreign market, demand is primarily due to individual orders for modified RNA oligonucleotides of a special structure containing complex modifications for targeted delivery of therapeutic RNA to target cells.

Information is posted in Album of promising developments of the NAS of Belarus organizations for the real sector of the economy (2023), p. 161-162. (in Russian)
Advantages and Innovations
In terms of purity, they are not inferior to imported analogues. Biological activity is confirmed by publications in rating international journals.

Possibility of introducing a wide range of modifications using reagents of our own production.

The developed technologies are environmentally safe.

RNA oligonucleotides are produced under conditions of automated solid-phase synthesis by highly qualified personnel on specialized equipment.
Stage of development
Already on the market
Funding source
State budged
Internal
IPR status
Exclusive rights
Secret know-how
Sector group
BioChemTech
Healthcare

Organization information

Type
R&D institution
Year established
1929
NACE keywords
C.20.59 - Manufacture of other chemical products n.e.c.
C.21.10 - Manufacture of basic pharmaceutical products
E.36.00 - Water collection, treatment and supply
M.72.19 - Other research and experimental development on natural sciences and engineering
M.74.90 - Other professional, scientific and technical activities n.e.c.
Turnover (in EUR)
10-20M
Already engaged in transnational cooperation
Yes
Additional comments
The Institute is a world leader in the development, production and use of ion-exchange fibrous materials and artificial substrates for plant cultivation. The Institute's work in the field of membranes and membrane technologies is widely known. Membrane materials for ultra- and microfiltration in the form of continuous webs and capillaries, cassette, roll and hollow fiber elements for use in energy, food, pharmaceutical, electronic and other industries have been developed and manufactured.

The Institute's scientists have discovered and studied the reactions of: heterocyclization of azomethines with carbonyl compounds, hydroamination of oxygen-containing compounds, initiated decarboxylation of mercury acylates, construction of an isothiazole cycle from 2-nitropentachlorobutadiene and sulfur. Convenient methods for synthesizing benzoquinolines, amines, pyridines, organomercury compounds, electrochemical methods for obtaining p-complexes of transition metals, methods for synthesizing various functional substituted organohalogen compounds, carboranes and peroxides have been developed.

The catalysts developed at the Institute have been implemented at the largest chemical plants. An antiblock composition preventing cellophane film from sticking together during its production has been implemented on an industry-wide scale. An industrial radiation-chemical technology for obtaining the blood plasma substitutes "Rondeks" and "Neorondex" has been developed.

The Institute's activities are aimed at developing scientific principles and technologies for creating new polymeric materials with special properties (selectively permeable, sorption, ion-exchange, catalytically active) for use in industry, ecology, agriculture, water treatment; development of methods for the synthesis and technologies for obtaining medicinal substances based on amino acids and their derivatives, biologically active substances and compositions for medicine and agriculture, functionally substituted organic and organoelement compounds.

The Institute carries out international scientific and technical cooperation within the framework of direct agreements with scientific institutions of Russia, Ukraine, Germany, Poland, Sweden, China, etc. Much attention is paid to the implementation of contracts for the conduct of research and development work and the manufacture of high-tech commercial products based on its own developments with organizations and firms in Saudi Arabia, Germany, Korea, Russia, and the USA.
Languages spoken
English
Russian

Information about partnership

Type of partnership considered
Distribution services agreement
Manufacturing agreement
Type and role of partner sought
Consumers interested in purchasing synthetic RNA oligonucleotides, guide RNA for CRISPR genome editing technology, modified RNA oligonucleotides under a manufacturing agreement.

Partners interested in purchasing synthetic RNA oligonucleotides, guide RNA for CRISPR genome editing technology, modified RNA oligonucleotides under a distribution services agreement.
Type and size of partner sought
> 500
251-500
SME 51-250
SME 11-50
SME <= 10
R&D Institution
University
Sole proprietor

Attachments

Просмотров: 69
Статистика ведется с 06.11.2024 14:25:22